<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>GA TB Reference Guide</title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>

<div class="uk-container">
    <p>
        Two FDA-approved IGRA tests are commercially available in the
        U.S. These include the QuantiFERON-TB Gold Plus (QFT) test and
        the TSPOT.TB (TSPOT) test. Guidelines on the use of these IGRAs
        as diagnostic tests for LTBI have been published by the American
        Thoracic Society (ATS), CDC, and the Infectious Diseases Society
        of America (IDSA) [Clin Infect Dis 2017; 64(2):111–5]. IGRAs are invitro blood tests that are based on
        interferon-γ (IFN-γ) release
        after stimulation by relatively TB-specific antigens (i.e., ESAT-6
        and CFP-10 in both assays). The QFT is a whole blood assay that
        uses an ELISA technique to measure IFN-γ production. TSPOT
        uses peripheral blood mononuclear cells (PBMCs) and detects (by
        use of ELISPOT) the number of T cells producing IFN-γ. Because
        the antigens used in the IGRAs are not found in M. bovis BCG (or
        most non-tuberculous mycobacteria), the IGRAs are more specific than the TST when used to test persons who have
        received
        BCG vaccination and do not cross react with most nontuberculous mycobacteria. Criteria on what constitutes a
        positive
        IGRA test have been published and are shown in
        <a href="#table_1_interpretation_criteria_for_the_quantiferon_tb_gold_plus_test">Tables 1</a>
        and
        <a href="#table_2_interpretation_criteria_for_the_t_spot_tb_test">Tables 2</a>.
    </p>
    <div class="uk-overflow-auto" id="table_1_interpretation_criteria_for_the_quantiferon_tb_gold_plus_test">
        <table class="uk-table uk-table-small uk-table-divider">
            <tbody>
            <tr>
                <th>Nil (IU/ml)</th>
                <th>TB1 minus Nil (IU/ml)</th>
                <th>TB2 minus Nil (IU/ml)</th>
                <th>Mitogen minus Nil</th>
                <th>QFT-Plus Result</th>
                <th>Report/Interpretation</th>
            </tr>
            <tr>
                <td colspan="1" rowspan="4">&lt; 8.0</td>
                <td>&gt; 0.35 and &gt; 25% of Nil</td>
                <td>Any</td>
                <td colspan="1" rowspan="2">Any</td>
                <td colspan="1" rowspan="2">Positive</td>
                <td colspan="1" rowspan="2">M. <i>tuberculosis </i>infection likely</td>
            </tr>
            <tr>
                <td>Any</td>
                <td>&gt; 0.35 and &gt; 25% of Nil</td>
            </tr>
            <tr>
                <td>&lt; 0.35 or &gt; 0.35 and &lt; 25% of Nil</td>
                <td>&lt; 0.35 or &gt; 0.35 and &lt; 25% of Nil</td>
                <td colspan="1">&gt; 0.50&nbsp;</td>
                <td>Negative</td>
                <td>M. <i>tuberculosis </i>infection NOT likely</td>
            </tr>
            <tr>
                <td>&lt; 0.35 or &gt; 0.35 and &lt; 25 % of Nil</td>
                <td>&lt; 0.35 or &gt; 0.35 and &lt; 25% of Nil</td>
                <td colspan="1">&lt; 0.50</td>
                <td colspan="1" rowspan="2">Indeterminate</td>
                <td colspan="1" rowspan="2">Likelihood of M. <i>tuberculosis </i>infection cannot be determined</td>
            </tr>
            <tr>
                <td colspan="1">&gt; 8.0</td>
                <td colspan="3" rowspan="1">Any</td>
            </tr>
            </tbody>
        </table>
    </div>

    <p>
        <b>Source</b>: Based on manufacturer recommendations for QuantiFERON-TB Gold Plus [Package insert]. <br>Available
        at:
        <a href="https://www.quantiferon.com/us/wp-content/uploads/sites/13/2020/01/L1095849-R06-QFT-Plus-ELISA-IFU.pdf">
            https://www.quantiferon.com/us/wp-content/uploads/sites/13/2020/01/L1095849-R06-QFT-Plus-ELISA-IFU.pdf</a>

    </p>

    <div class="uk-overflow-auto" id="table_2_interpretation_criteria_for_the_t_spot_tb_test">
        <table class="uk-table ">
            <thead>
            <tr>
                <th>Interpretation</th>
                <th>Nil*</th>
                <th>TB Response&dagger;</th>
                <th>Mitogen&sect;</th>
            </tr>
            </thead>
            <tbody>
            <tr>
                <td>Positive&para;</td>
                <td>&le;10 spots</td>
                <td>&ge;8 spots</td>
                <td>Any</td>
            </tr>
            <tr>
                <td>Borderline**</td>
                <td>&le;10 spots</td>
                <td>5, 6, or 7 spots</td>
                <td>Any</td>
            </tr>
            <tr>
                <td>Negative&dagger;&dagger;&nbsp;</td>
                <td>&le;10 spots</td>
                <td>&gt;20 spots</td>
                <td>&gt;20 spots</td>
            </tr>
            <tr>
                <td>Invalid**</td>
                <td>&le;10 spots</td>
                <td>Any</td>
                <td>Any</td>
            </tr>
            <tr>
                <td>&nbsp;</td>
                <td>&le;10 spots</td>
                <td>&lt;5 spots</td>
                <td>&lt;20 spots</td>
            </tr>
            </tbody>
        </table>

    </div>
    <p>
        <b>Source</b>: Based on Oxford Immunotec T-Spot.TB package insert. <br>
        Available at: <a
            href="http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf ">
        http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf
    </a>
    </p>

    <p>* The number of spots resulting from incubation of PBMCs in culture media without antigens. <br>
        † The greater number of spots resulting from stimulation of peripheral
        blood mononuclear cells (PBMCs) with two separate cocktails of peptides
        representing early secretory antigenic target-6 (ESAT-6) or culture filtrate
        protein-10 (CFP-10) minus Nil. <br>
        § The number of spots resulting from stimulation of PBMCs with mitogen
        without adjustment for the number of spots resulting from incubation of
        PBMCs without antigens. <br>
        ¶ Interpretation indicating that Mycobacterium tuberculosis infection is
        likely. <br>
        ** Interpretation indicating an uncertain likelihood of M. tuberculosis infection. In the case of Invalid
        results, these should be reported as “Invalid”
        and it is recommended to collect another sample and retest the individual. <br>
        †† Interpretation indicating that M. tuberculosis infection is not likely. </p>

</div>
</body>

<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
</html>